Akums gets approval for triple combination diabetes treatment

Cipla partners with MNCs to strengthen anti-diabetes innovative portfolio: GlobalData

Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.

LyGenesis and Imagine Pharma to jointly develop cell therapies for Patients with Type 1 diabetes

Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes

Cipla signs agreement with Novartis for diabetes therapy Galvus range

Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore

Sanofi receives marketing approval for its diabetes drug Soliqua in India

Pre-filled pens containing a combination of insulin glargine 100 Units/mL and lixisenatide for once-daily dosing

MindRank gets USFDA clearance of IND application for MDR-001 for treatment of Type 2 diabetes

MindRank expects to initiate a Phase I safety study in the first quarter of 2023.

Glenmark launches Triple FDC of Teneligliptin with Pioglitazone and Metformin for adults with Type 2 Diabetes

This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation

Steps taken by Govt. to support diabetes patients

As per 10th edition of International Diabetes Federation (IDF) Atlas, 2021, India has 74.2 million people with diabetes between the age of 20-79 years

Infosys Foundation opens second Diabetes Reversal Counselling Centre in Nagpur

Through lifestyle modifications, ADORE will assess the progress of patients based on parameters like reduction in blood sugar levels and weight, among others

Experts highlight the rising cases of diabetes in youngsters

India is home to nearly 80 million diabetics and this number is expected to rise to a staggering 134 million in the next 25 years.